Supremes bolster preemption defense

Share this article:

In a major test of the preemption principle, the US Supreme Court ruled 8-1 that patients can't file common-law claims challenging the safety and effectiveness of an FDA-approved medical device.

The case, Riegel v. Medtronic, involved a suit by the family of a man injured when a balloon catheter made by Medtronic burst while he was undergoing angioplasty after suffering a heart attack.

Writing for the majority, Justice Antonin Scalia said “Premarket approval is a ‘rigorous' process” that should preempt state laws.

The lone dissenter was Justice Ruth Bader Ginsburg.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.